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Background: γ-Glutamyl transpeptidase 1 (GGT1) is an N-glycosylated membrane protein that catabolizes
extracellular glutathione and other γ-glutamyl-containing substrates. In a variety of disease states, including tumor
formation, the enzyme is shed from the surface of the cell and can be detected in serum. The structures of the
N-glycans on human GGT1 (hGGT1) have been shown to be tissue-specific. Tumor-specific changes in the glycans
have also been observed, suggesting that the N-glycans on hGGT1 would be an important biomarker for detecting
tumors and monitoring their progression during treatment. However, the large quantities of purified protein
required to fully characterize the carbohydrate content poses a significant challenge for biomarker development. Herein,
we investigated a new antibody-lectin sandwich array (ALSA) platform to determine whether this microanalytical technique
could be applied to the characterization of N-glycan content of hGGT1 in complex biological samples.
Results: Our data show that hGGT1 can be isolated from detergent extracted membrane proteins by binding to the ALSA
platform. Probing hGGT1 with lectins enables characterization of the N-glycans. We probed hGGT1 from normal human
liver tissue, normal human kidney tissue, and hGGT1 expressed in the yeast Pichia pastoris. The lectin binding patterns
obtained with the ALSA platform are consistent with the hGGT1 N-glycan composition obtained from previous large-scale
hGGT1 N-glycan characterizations from these sources. We also validate the implementation of the Microcystis aeruginosa
lectin, microvirin, in this platform and provide refined evidence for its efficacy in specifically recognizing high-mannose-type
N-glycans, a class of carbohydrate modification that is distinctive of hGGT1 expressed by many tumors.
Conclusion: Using this microanalytical approach, we provide proof-of-concept for the implementation of ALSA in
conducting high-throughput studies aimed at investigating disease-related changes in the glycosylation patterns on
hGGT1 with the goal of enhancing clinical diagnoses and targeted treatment regimens.
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γ-Glutamyl Transpeptidase 1 (GGT1), is a clinically im-
portant enzyme that has been studied for over 95 years.
Expressed on the surfaces of a variety of ductal and glan-
dular epithelial cells throughout the body, GGT1 is stra-
tegically localized to catalyze the cleavage of glutathione
in circulating fluids, allowing for the recovery of its* Correspondence: marie-hanigan@ouhsc.edu
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unless otherwise stated.constituent amino acids [1,2]. As such, GGT1 plays a key
role in cysteine homeostasis [3]. However, abnormal ex-
pression and localization patterns of GGT1 are common
in several human malignancies, including liver, kidney,
prostate, pancreatic, ovarian, colon, and lung cancers
[4-7]. The induction of GGT1 expression has been shown
to protect tumors against oxidative stress by initiating the
recovery of amino acids from extracellular glutathione for
its intracellular synthesis, conferring GGT1-positive tu-
mors with enhanced resistance to alkylating agents and
other classes of chemotherapeutic drugs [8-10]. While ele-
vated serum levels of GGT1 associated with liver andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for monitoring disease progression and response to clin-
ical intervention, its utility as a pre-symptomatic cancer
biomarker has been hampered by the fact that high serum
GGT1 levels are also observed in non-malignant diseases,
ranging from alcoholic hepatitis to myocardial infarction
[11-13]. Thus, the potential of serum GGT1 as a diagnos-
tic marker of tumor formation and progression has been
discounted historically.
Human GGT1 (hGGT1, Swiss-Prot: P19440), is a type II
membrane-bound glycoprotein composed of two asymmet-
ric subunits, possessing seven potential N-glycosylation
sites [sequon NX(S/T), X ≠ P], with six sites on the large
subunit and a single site on the small subunit [14-16].
Using high-resolution mass spectrometry, we have previ-
ously shown that all seven of these asparagine residues are
capable of being glycosylated when hGGT1 is expressed in
normal human tissues and have demonstrated that the
structure and composition of the N-glycans vary in a
tissue-specific manner [17]. While it has long been appre-
ciated that the structural compositions of the N-glycans
on hGGT1 change during malignant transformation, the
large quantities of the tumor-derived glycoprotein re-
quired to characterize its carbohydrate content has posed
a significant challenge for differential analyses [18-25].
Moreover, conventional methods, such as comparative lec-
tin blotting or affinity chromatography coupled with mass
spectrometry are labor-intensive and sample-exhaustive.
Thus, the development of a more facile, high-throughput
analytical method for reproducibly detecting differences in
N-glycan content on small quantities of hGGT1 in com-
plex biological samples would be of considerable benefit
for investigative and diagnostic studies.
A promising emerging methodology for potentially
addressing each of these intrinsic obstacles is antibody-
lectin sandwich array (ALSA) technology [26]. Adapting
existing multiplexed protein technology, ALSA couples
the immuno-capture of glycoproteins from biological
samples, using target-specific antibodies, with the ability
to interrogate the bound target with a variety of bio-
tinylated probes. Thus, a diverse group of lectins or gly-
can binding antibodies can be used to simultaneously
probe for a variety of carbohydrate moieties or gly-
coepitopes on a glycoprotein of interest with a very small
amount of starting material. Unlike most large-scale
approaches, this methodology introduces an objective
quantitative component that enhances the interpretative
value associated with the qualitative changes that it
detects. The amount of fluorophore-labeled streptavi-
din bound by a specific biotinylated probe at each cap-
ture site is directly related to the prevalence of a particular
glycan modification [27]. Therefore, considerable com-
positional information can be gleaned from a single,
small-scale sample preparation, a feature of ALSAwhich has been widely exploited for a diverse array of
pathologies [28-30].
In recent years, glycans have experienced a renaissance
as potential biomarkers of cancer and other human
pathologies [31-34]. A great deal of effort has been de-
voted to developing techniques for characterizing and
cataloging changes in disease-related glycosylation pat-
terns. Historically, however, methodological approaches
that have exploited the use of glycan binding proteins
[35] have required relatively large samples for conduct-
ing discriminatory comparisons, and as a result, primary
screening using glycan binding proteins could exhaust
all of a sample before the optimal discriminatory lectin
is even identified [36]. While the use of alternative com-
plementary approaches, such as mass spectrometry,
can provide finer structural resolution of glycosylation
changes within individual samples, these techniques are
not optimal for making simultaneous quantitative com-
parisons of glycan content between multiple sample pools,
thus limiting their utility for primary biomarker screening
[37]. The recent advent of ALSA has attempted to address
these inherent technical limitations.
In the current study, we investigated whether the micro-
analytical advantages of the ALSA platform could be ap-
plied to the differential characterization of hGGT1 purified
from disparate sources and bearing distinct, pre-defined
N-glycan content. We show that immuno-captured hGGT1,
originating from microgram quantities of either normal
human liver tissue, normal human kidney tissue, or from
hGGT1 expressed in the yeast Pichia pastoris, exhibits
distinct ALSA binding patterns that complement results ob-
tained from previous large-scale hGGT1 N-glycan character-
izations from these sources. We also demonstrate the first
use of the Microcystis aeruginosa lectin, microvirin (MVN),
in this type of screening assay and provide evidence for its
utility in specifically recognizing high-mannose-type
N-glycans on hGGT1, a modification which is apparently
unique to hGGT1 isoforms expressed in malignant kidney
and liver tissues [19,21]. Hence, we provide proof of
principle support for the implementation of ALSA in
carrying out future high-throughput studies aimed at
investigating changes in the glycosylation patterns on
hGGT1 associated with human pathophysiological pro-
cesses. We anticipate that this approach can be applied to
developing primary diagnostic screening strategies and/or
the development of a hGGT1 biomarker in studies evalu-
ating therapeutic intervention.
Results
Glycan microarray analysis to determine the fine
carbohydrate binding specificity of microvirin
MVN has previously been shown to contain a single
carbohydrate recognition domain (CRD) that can bind
Manα(1–2)Man- linkages, the terminal disaccharide units
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rides [38,39]. To more precisely and comprehensively de-
termine the ligand specificity of the CRD of MVN,
biotinylated MVN (at concentrations of 2, 20, and
200 μg/mL) was subjected to high-throughput glycan
array screening among 611 structurally-defined carbo-
hydrates by Core H of the Consortium for Functional
Glycomics (CFG) utilizing Version 5.0 of the printed
glycan microarray (Figure 1). The highest affinity carbo-
hydrates from the 200 μg/mL data set are rank-ordered
in Table 1. Unambiguous positive binding of MVNFigure 1 Glycan array analysis of MVN CRD specificity. (A) Binding pro
different carbohydrate structures. Relative fluorescence units reflect relative
are indicated by their CFG array numbers (see Table 1). The diagram is bas
http://www.functionalglycomics.org/glycomics/publicdata/selectedScreens.
200 μg/mL as ranked by fluorescence intensity (from 200 μg/mL data set)
Binding was considered positive if the RFU value was greater than the prim
All 11 carbohydrates with above-threshold RFU values contained a Manα(1
differences that could be attributed to presence of the central arm Manα(1occurred with ten glycans, each of which contained the
Manα(1–2)Man- motif (Figures 1A and 2).
To discriminate between primary and secondary bind-
ing specificities, we applied Outlier Motif Analysis to
the 200 μg/mL MVN CFG data set. This analytical tool
has been described previously as a method for refin-
ing the inherent specification of binding determinants
from complex data sets such as those compiled from
CFG glycan arrays [40]. From this analysis, MVN exhib-
ited a clear demarcation between bound and unbound
states (fluorescence threshold =2,319 RFU), with thefile of MVN at 200 μg/mL, using the CFG array V5.0 harboring 611
affinities toward the corresponding glycan. Glycans bound by MVN
ed on the primary CFG data spreadsheets, which can be accessed at
jsp (Glycan Array #2340). (B) MVN glycan array binding at 2, 20,
and apparent binding affinity as determined by Outlier Motif Analysis.
ary fluorescence threshold, calculated to be 2,319 RFU (see Figure 2).
-2)Man- determinant, and the four shown illustrate the binding affinity
-2)Man-disaccharide. Symbols: blue box, GlcNAc; green circle, mannose.
Table 1 High-affinity ligands of microvirin from the CFG's
glycoarray analysis





























aExpressed as a percentage of the highest-affinity ligand, which exhibited a
fluorescence reading of 19,838 RFU at 200 μg/mL microvirin.
West et al. BMC Biotechnology    Page 4 of 16Manα(1–2)Man- moiety serving as the common motif
in all of the bound glycans (Figure 2A and B). More-
over, this motif was not present within any of the un-
bound constituents on the CFG glycan array. Other 2’
substituted mannose motifs, such as GlcNAcβ(1–2)
Man-, a glycan well-represented within Version 5.0 of
the CFG glycan array and a binding determinant for
the Lens culinaris agglutinin (LCA) lectin, were not
bound by MVN. Since the Manα(1–2)Man- motif ad-
equately discriminated the bound versus unbound carbo-
hydrates within the CFG data set for MVN, we then
screened for motifs among the ten MVN-bound struc-
tures which might explain the varied binding within this
group. Among the MVN-bound structures that contained
a chitobiose core motif (GlcNAcβ [1-4] GlcNAc, i.e. bona
fide N-glycans), the presence of an intervening Manα(1–2)
Man linkage on the central arm of the N-glycan structure
resulted in decreased MVN binding affinity (Figure 1B and
Table 1). Strikingly, the two carbohydrate structures to
which MVN bound with the highest- and lowest-affinity
among the ten positive hits on the CFG glycan array varied
by the absence or presence, respectively, of a single
Manα(1–2)Man- substituent at this position (Figure 1B
and Table 1). This observation may indicate that MVN
exhibits preferential affinity for structural or rotational
isomers with less restricted access to the Manα(1–2)
Man- binding determinant (Figure 2B). This analysis vali-
dates the utility of MVN as a unique carbohydrate binding
protein that specifically targets a structural motif that ispresent within the type of high-mannose N-glycans that
are most commonly encountered in biological samples.
Characterization of human GGT1 expressed in Pichia
pastoris as a potential substrate pool that is exclusively
modified with high-mannose-type N-glycans
We previously showed that pools of hGGT1 purified from
normal human kidney and liver tissue are each modified
by a specific array of virtually non-overlapping complex-
type N-glycans, with no high-mannose-type structures ob-
served on hGGT1 glycopeptides originating from either of
these tissues (Figure 3 and [17]). Indeed, high-mannose-
type N-glycans on hGGT1 have only been observed in
samples of diseased tissues from these organs [19,21]. To
evaluate the utility of our hGGT1 microanalytical system
and the diagnostic efficacy of our biotinylated MVN-
reagent in assessing disease status, we generated hGGT1
modified with high-mannose-type structures. Others have
shown that Pichia pastoris N-glycosylates recombinant hu-
man proteins with high-mannose-type structures [41-43],
and we previously demonstrated that hGGT1 expressed in
and purified from the yeast Pichia pastoris (Pp-hGGT1) is
N-glycosylated and retains full enzymatic activity [15,16,44].
To investigate the N-glycan content of purified Pp-hGGT1,
total N-glycans were enzymatically-released with the endo-
glycosidase PNGase F and profiled by MALDI-TOF/MS
(Figure 4A). A family of ions were observed corresponding
to predicted N-glycans that included Man8GlcNAc2 (4%),
Man9GlcNAc2 (49%), Man10GlcNAc2 (37%), Man11GlcNAc2
(8%), and Man12GlcNAc2 (2%), consistent with findings
from other recombinant human glycoproteins expressed in
Pichia pastoris [41,43].
The distribution of N-glycans at different sites was ad-
dressed by LC-MS/MS profiling of tryptic glycopeptides,
using diagnostic oxonium ions at m/z 163.0 and 204.1 to
initially identify glycopeptide families, which elute as
discrete chromatographic units [17]. As an example
(Figure 4B), the N-glycans on the LAFATMFNSSEQSQK
(Asn-120) hGGT1 glycopeptide approximately corres-
pond to the range of high-mannose-type compositions
found in total Pp-hGGT1 (Figure 4A). Collision-induced
dissociation MS/MS was carried out to confirm the struc-
ture models, as illustrated by fragmentation (Figure 4C) of
the triply-charged glycopeptide bearing a Man11GlcNAc2
glycan (m/z = 1293.2) to yield a spectrum of triply-, doubly-
and singly-charged ions, including the core GlcNAc-
modified peptide (m/z = 946.5) (Figure 4C). Similar
N-glycan microheterogeneity was observed at Asn344
and Asn511, of the large and small subunits, respectively
(Table 2). These results support the use of Pp-hGGT1
as a pool of hGGT1 that is uniformly modified by high-
mannose type N-glycans (Figure 3).
To evaluate whether purified Pp-hGGT1 is a high-
affinity ligand of MVN, this pool was subjected to lectin
Figure 2 Outlier Motif Analysis of the fine carbohydrate specificity of microvirin. (Upper Panel) The fluorescence values for each glycan
interaction exhibited by microvirin on the Consortium for Functional Glycomics Glycan Array #2340 at a concentration of 200 μg/mL were
graphed in order of apparent intensity to determine the fluoresence threshold of positive interactions. Microvirin exhibited a clear demarcation
between bound and unbound states on the array, and an unambiguous cut-off value of 2,319 relative fluorescence units (RFUs) was established.
(Lower Panel) Outlier Motif Analysis was employed on the data set shown in (Upper Panel), according to the previously described method [40].
From this analysis it was determined that the presence of a Manα(1-2)-motif was necessary and sufficient for microvirin binding, while the presence of an
intervening Manα1-2-linkage on the central arm of the chitobiose core structure of bound N-linked glycans reduced the affinity for microvirin for high-
mannose structures. Using the refinement qualifier “Manα1,2 NO Manα1,2 on the central arm,” the summed motif scores for each glycan were plotted
with respect to fluorescence intensity after detection with microvirin, which resulted in further segregation of high affinity carbohydrate motifs from the
weaker affinity motifs. The dashed line represents the threshold for defining outliers, based on the distributions from all the glycans.
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an antibody specific for a peptide on the C-terminus of
the large subunit of hGGT1. As shown in Figure 5, MVN
and anti-hGGT1 similarly recognized the large subunit,
which migrates broadly owing to microheterogeneity at
the six N-glycosylation sites (Figure 5, lanes 1 and 3 and
[15]). Enzymatic deglycosylation collapses Pp-hGGT1 into
a sharper band, which is no longer recognized by MVN(Figure 5, lanes 2 and 4). These results demonstrate that
MVN recognizes Pp-hGGT1 by virtue of its N-glycans.
Differential profiling of hGGT1 glycoepitopes by ALSA
We next investigated whether MVN and other lectins
could be utilized in conjunction with ALSA technology
to illuminate differences in carbohydrate content on the
low quantities of hGGT1 present within complex
Figure 3 Source-specific composition of N-glycans on human GGT1 (hGGT1). A graphical summary of the predominant structural features of
the N-glycans identified on hGGT1 expressed in normal human kidney (left panel) and liver (middle panel) tissues and Pichia pastoris (right panel)
is shown. Kidney hGGT1 N-Glycans are dominated by complex type bisected bi- and triantennary structures with a high degree of fucosylation
on core and peripheral GlcNAc residues and a low degree of sialylation. Liver hGGT1 N-glycans are dominated by complex-type biantennary
structures with a high degree of sialylation and a low degree of core and peripheral fucosylation with modest contributions of triantennary structures.
Pichia pastoris-expressed hGGT1 is modified by high-mannose-type N-glycans, ranging in size from Man7GlcNAc2 to Man13GlcNAc2. Symbols: blue box,
GlcNAc; green circle, mannose; yellow circle, galactose; red triangle, fucose; purple diamond, N-acetylneuraminic acid.
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previously-characterized polyclonal antibody (GGT129)
that binds a C-terminal epitope in the large subunit of
hGGT1 was immobilized and chemically-derivatized to
prevent recognition by lectins or glycan-specific anti-
bodies. The region containing the antibody epitope is
not predicted to undergo post-translational modification
[2].
We first asked whether the immobilized hGGT1 anti-
body was able to capture the hGGT1 that was produced by
normal human kidney tissue, normal human liver tissue,
and Pichia pastoris. As shown in Figure 6C, the immobi-
lized antibody immuno-captured equivalent amounts of
hGGT1 from each pool of activity-normalized hGGT1, in-
dicating that the method was appropriate for comparative
analyses. Furthermore, a two-fold dilution of hGGT1 typic-
ally resulted in reduced signal (Figure 7), suggesting that
lectin binding was approximately proportional to hGGT1
levels. From this analysis, a detection limit of approximately
0.3 nanograms for Pichia pastoris-expressed hGGT1 was
achieved. Based on activity normalization of the sample
pools and their similar dilution profiles, this also pro-
vides an estimate for the detection limits achieved for the
immuno-captured hGGT1 in the more complex kidney
and liver extracts, as well (Figure 7).
The results from probing the captured hGGT1s with a
variety of glycan binding proteins are depicted in Figure 6
(panels B and C) and summarized in Table 3. MVN bound
only Pp-hGGT1, consistent with exclusive expression of
high-mannose type N-glycans on hGGT1 from this source.
Concanavalin A (ConA), which exhibits strong affinity for
high-mannose type N-glycans, also bound only Pp-hGGT1
(Figure 7). ConA also has weak affinity for complex type N-
glycans, which we would expect to be present on the liver-
and kidney-derived hGGT1, but under the conditions of
our assay, no binding was observed on hGGT1 in thesesample pools. Galanthus nivalis lectin (GNL), which like
ConA also has strong affinity for high-mannose type N-gly-
cans and weak affinity for complex N-glycans [45,46], also
bound only Pp-hGGT1 (Figure 7). The similar binding pat-
terns observed for MVN, ConA, and GNL are consistent
with the presence of high-mannose type N-glycans on Pp-
hGGT1 but not on the kidney- or liver-derived hGGT1.
Euonymus europaeus lectin (EEL) binds α-linked galact-
ose primarily in the context of blood group B [Galα1-3
(Fucα1-2)GlcNAc], and more weakly to α1-2 linked
fucose [47,48]. As shown in Figure 7, EEL exhibited clear,
concentration-dependent affinity for kidney-derived
hGGT1. EEL also exhibited greater affinity for Pp-hGGT1
than liver-derived hGGT1 with increasing sample input
(Figure 7). Griffonia simplicifolia Lectin 1(GSL-1) similarly
binds terminal α-linked galactose but also α-linked GalNAc
[49], and its affinity pattern for kidney- and liver-derived
hGGT1 was similar to that measured for EEL at the higher
sample dilution (Figure 7). However, unlike EEL, its affinity
pattern for Pp-hGGT1 exceeded that observed for kidney-
derived hGGT1 with increasing sample concentrations.
ECL, which has specificity primarily for terminal Galβ1-
4GlcNAc [50], exhibited high affinity for both Pp-hGGT1
and kidney-derived hGGT1 at both sample dilutions, al-
though its apparent affinity for Pp-hGGT1 exceeded that
for kidney hGGT1 on the array. Together, these results sug-
gest the presence of terminal galactose, either α- or β-
linked, on hGGT1 from kidney and Pichia pastoris. How-
ever, while we have demonstrated these glycan motifs on
human kidney-derived hGGT1 (Figure 3 and [17]), we have
no evidence that they are present on Pp-hGGT1, which is
restricted to the production of high-mannose type carbohy-
drate motifs. Therefore, the affinity pattern of this particular
subgroup of lectins for Pp-hGGT1 may arise from an inher-
ent, yet cryptic, binding of high-mannose type N-glycans, a
possibility that has recently been confirmed for EEL [51].
Figure 4 (See legend on next page.)
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Figure 4 Glycoconjugate analysis of hGGT1 expressed in Pichia pastoris. (A) MALDI-TOF-MS profile of neutral N-glycans released by PNGase
F from purified Pp-hGGT1. Ions corresponding to monosodiated N-glycans known to be expressed by Pichia pastoris are assigned. Symbols: blue box,
GlcNAc; green circle, mannose. (B) Averaged LC/Q-Star MS spectrum for the Asn-120 (LAFATMFNSSEQSQK) family of glycopeptides from Pp-hGGT1,
showing the identified glycoconjugates within their elution interval. Asterisks denote glycoconjugates that were confirmed by tandem MS analysis.
P represents the LAFATMFNSSEQSQK tryptic peptide to which the N-glycans are attached. Unannotated peaks represent co-eluting nonglycosylated
hGGT1 peptides. (C) MS/MS spectrum showing fragmentation of the Man11GlcNAc2-modified glycopeptide (m/z =1293.2) shown in (B).
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bound at saturating levels to kidney-derived hGGT1,
weakly to liver-expressed hGGT1, and not at all to Pp-
hGGT1 (Figures 6 and 7). The “hook effect” observed
for DSL binding to kidney hGGT1, is commonly ob-
served in immunoassays and other multivalent binding
assays at saturating levels of the analyte [52]. DSL has
specificity for N-acetyl-lactosamine (LAcNAc, Galβ1-
4GlcNAc), as typically found on extended N-glycans
[53]. This binding pattern is consistent with both the
greater size and heterogeneity of complex type N-glycans
which we identified on kidney-derived hGGT1 and dem-
onstrated were not present on liver-derived hGGT1 or
Pp-hGGT1 (Figures 3 and 4 and [17]).Table 2 N-glycan microheterogeneity of human GGT1
expressed in Pichia pastoris as determined by LC-MS/MS
(see Figure 4)
hGGT1
N-glycosylation Theoretical Mass MS/MS
Site N-glycan Mass Measured Support
[M + 3H] + 3
N120 Man8GlcNAc2 1131.1307 1131.1153 ✓
Man9GlcNAc2 1185.1483 1185.1520 ✓
Man10GlcNAc2 1239.1659 1239.1576 ✓
Man11GlcNAc2 1293.1835 1293.1609 ✓
Man12GlcNAc2 1347.2011 1347.1885 ✓
Man13GlcNAc2 1401.2187 1401.2055 ✓
[M + 3H] + 3
N344 Man7GlcNAc2 985.7410 985.7221 ✓
Man8GlcNAc2 1039.7586 1039.7490 ✓
Man9GlcNAc2 1093.7762 1093.7745 ✓
Man10GlcNAc2 1147.7938 1147.7869 ✓
Man11GlcNAc2 1201.8114 1201.8104 ✓
Man12GlcNAc2 1255.829 1255.8137 ✓
[M + 3H] + 3
N511 Man8GlcNAc2 1112.8331 1112.8189
Man9GlcNAc2 1166.8507 1166.8450 ✓
Man10GlcNAc2 1220.8683 1220.8614 ✓
Man11GlcNAc2 1274.8859 1274.8865 ✓
Man12GlcNAc2 1328.9035 1328.8865 ✓
Man13GlcnNAc2 1382.9211 1832.9140 ✓Phaseolus vulgaris-Erythroagglutinin (Pha-E) specifically
binds bisected N-linked glycans [54]. As Pha-E exhibited
weaker binding affinity overall, we used higher concentra-
tions (i.e. reduced dilutions) of hGGT1 for these analyses
(Figures 6C and 7). The detection of bisecting GlcNAc on
kidney-derived hGGT1 is consistent with our previous
mass spectrometric analysis of hGGT1 isolated from this
tissue source (Figure 3 and [17]). This type of modification
is restricted to complex type N-glycans. Thus, the lack of
interaction between Pha-E and Pp-hGGT1 is consistent
with the expected absence of complex type N-glycans
(Figure 4). Moreover, our mass spectrometric analysis did
not detect bisected N-glycans on hGGT1 expressed in nor-
mal human liver, lending further credibility to the specifi-
city of the ALSA platform and the specificity of the lectin
binding pattern (Figure 3 and [17]).
Lectin affinity blot validation of key source-specific
differences in hGGT1 N-glycan content identified by ALSA
microanalyses
ALSA analysis of hGGT1 expressed in Pichia pastoris
and normal human kidney and liver revealed discrimin-
atory lectin binding patterns that were consistent withFigure 5 MVN binds high-mannose type N-glycans on Pp-hGGT1.
Purified Pp-hGGT1 was incubated in the absence or presence of
PNGaseF. Pp-hGGT1 (0.1 μg) from each reaction was resolved by
SDS-PAGE, electroblotted onto nitrocellulose, and probed with either
an antibody against the large subunit of hGGT1 (left panel) or with
biotinylated-MVN (right panel). MW, molecular weight markers.
Figure 6 Antibody lectin sandwich assay (ALSA). (A) Graphical depiction of ALSA strategy. The hGGT1 antibodies are printed on a
nitrocellulose slide and chemically derivatized to inactivate their glycans. hGGT1 is captured by the immobilized antibody and N-glycan
features are probed using biotinylated lectins, which are subsequently detected using streptavidin-phycoerythrin and fluorescence scanning.
(B) One printed antibody array well is shown with the magnified capture antibodies. Individual hGGT1 capture spots have been cut out to show
triplicate detection of Datura stramonium lectin (DSL) among 64-fold kidney sample dilutions (equivalent to ~75 ng of total extracted
kidney protein). (C) Representative results for hGGT1 capture antibody and detection reagents (indicated in the column labels).
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and Table 3). To support these microanalytical findings,
we investigated whether a subset of these binding patterns
could be confirmed using the more time- and sample-
exhaustive method associated with coupled immunopre-
cipitation and lectin blot analysis. Thus, hGGT1 was
immunoprecipitated from activity-normalized aliquots of
each class of hGGT1, and the bound fractions were sub-
jected to SDS-PAGE and subsequent lectin blotting analysis
with MVN, Pha-E, or DSL. ALSA analyses predicted that
MVN would uniquely bind to Pichia pastoris-expressed
hGGT1, while Pha-E would uniquely bind to kidney
hGGT1 (Table 3). In the absence of a lectin that only
bound liver hGGT1 in the ALSA platform, we used DSL,
which exhibited high affinity for kidney-expressed hGGT1,
modest affinity for liver-expressed hGGT1, and no appar-
ent affinity for Pichia pastoris-expressed hGGT1 (Table 3).As shown in Figure 8, western blot analysis against
hGGT1 confirmed that equivalent amounts of the pro-
tein were immuno-captured from the three samples and
revealed that Pp-hGGT1 exhibits greater microheteroge-
neity in its migration pattern relative to kidney- or liver-
derived hGGT1 (Figure 8, top panel). Previous studies
from our lab showed that all six of the N-glycosylation
sites on the large subunit of hGGT1 are occupied on the
kidney- and liver-expressed enzyme, while only five are
fully occupied on Pp-hGGT1 [15-17]. Therefore, these
distinct banding patterns may reflect differences in gly-
cosylation site occupancy or N-glycan composition. The
apparent non-specific bands in the hGGT1 blot are
likely the dissociated heavy chain of the rabbit IgG used
to immunoprecipitate hGGT1 being recognized by the
HRP-conjugated anti-rabbit secondary antibody used to
visualize the hGGT1. In the ALSA analyses, the antibody
Figure 7 Graphs of Pp-hGGT1, kidney hGGT1, and liver hGGT1 dilution series. Each graph shows representative plots of dilutions of Pichia
pastoris-expressed hGGT1, kidney extract hGGT1, and liver extract hGGT1 samples probed with the indicated lectins.
West et al. BMC Biotechnology    Page 10 of 16that is printed is chemically-modified to prevent interac-
tions between it and lectin probes or secondary antibodies
[26,55]. MVN probing confirmed the ALSA data, showing
specific recognition of Pp-hGGT1 (Figure 8, MVN panel,lane 1). Conversely, Pha-E exhibited strong, specific binding
to kidney hGGT1 (Figure 8, Pha-E panel, lane 2), with no
detectable binding to either Pichia pastoris- or liver-derived
hGGT1 (Figure 8, Pha-E panel, lanes 1 and 3), again
Table 3 Specificity of glycan binding proteins for hGGT1 from kidney, liver and Pp-hGGT1
Signal 2X higher than background
Detection Specificity Kidney Liver Pp-hGGT1
Anti-GGT1 hGGT1 Yes Yes Yes
Microvirin (MVN) Mannose No No Yes
Concanavalin A (ConA) terminal α-Man No No Yes
Galanthus nivalis (GNL) Man(terminal Manα(1-3)Man) No No Yes
Euonymus europaeus (EEL) Galα(1-3)Gal Yes No Yes
Erythrina cristagalli (ECL) Terminal Lac/LacNAc Yes No Yes
Griffonia simplicifolia (GSL-1) α-GalNAc, GalNAc α-Thr/Ser(T) and α-Gal Yes No Yes
Datura stramonium (DSL) (GlcNAc)n, polyLacNAc and LacNAc Yes Yes No
Phaseolus vulgaris Erythroagglutinin(Pha-E) Galb(1-4)GlcNAcβ(1-2)Man Yes No No
Figure 8 hGGT1 lectin blotting confirms differential ALSA
binding affinities. Membrane extracts from normal human
kidney and liver tissue or Pichia pastoris-expressed hGGT1 were
activity-normalized and subjected to immunoprecipitation with a
polyclonal anti-hGGT1 large subunit antibody. Equal volumes from
each immunoprecipitation eluate were resolved by SDS-PAGE and
affinity blotted with anti-hGGT1 (hGGT1, top panel) or the biotinylated
lectins, microvirin (MVN, second panel), Phaseolus vulgaris Erythroagglutinin
(Pha-E, third panel), and Datura stramonium lectin (DSL, bottom panel).
Expanded views of the immunoblots shown here along with the
relevant molecular weight markers are included in Additional file 1.
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binding preference for kidney hGGT1 and a modest inter-
action with liver hGGT1 (Figure 8, DSL panel, lanes 2
and 3), yet this lectin exhibited no apparent affinity for
Pichia pastoris-expressed hGGT1 (Figure 8, DSL panel,
lane 1). These results qualitatively recapitulate the quanti-
tative evaluations from the ALSA microanalyses and sup-
port the application of ALSA as a valid approach for
identifying differential hGGT1-specific lectin binding pat-
terns in small aliquots of simple (e.g. purified Pp-hGGT1)
and complex (e.g. tissue extracts) biological samples.
Discussion
With the goal of miniaturizing comparative glycoanalyses
on hGGT1, we incorporated the use of the highly-versatile
ALSA platform to discern whether it was capable of re-
producibly identifying differential lectin binding patterns
among human kidney and liver tissue sample preparations
of hGGT1, which have distinct N-glycan content. To aug-
ment the differential analysis, we generated a pool of
hGGT1 in the yeast Pichia pastoris that we confirmed by
mass spectrometry to be uniquely modified by high-
mannose type N-glycans (Figures 3 and 4), a structural
class of carbohydrates that are not observed on hGGT1
expressed in normal human kidney and liver tissues but
have been documented on hGGT1 expressed in human
malignancies [19,21]. We developed a biotinylated version
of the Microcystis aeruginosa lectin MVN as a reagent that
specifically interacts with high-mannose type N-glycans.
With the aid of Core H of the Consortium for Functional
Glycomics, we confirmed that MVN exhibits exquisite
specificity for Manα(1–2)Man disaccharide, confirm-
ing and extending the original analyses conducted by
Shahzad-ul-Hussan and colleagues on a more limited array
of glycans [39]. Using outlier motif analysis [40], we
gained new insights into the fine saccharide binding speci-
ficity of the carbohydrate recognition domain of MVN.
Our analysis suggests that an intervening Manα(1–2)Man
substituent comprising the central (B) arm of high-
West et al. BMC Biotechnology    Page 12 of 16mannose structures significantly reduces the affinity of
MVN (Figure 1B and Table 1). The affinity pattern of
MVN is distinct from the high-mannose binding lectins
GNL and ConA, which can cross-react with complex type
N-glycans [45,46].
With the help of this new reagent, we demonstrated
that the ALSA platform could reveal clear, precise distinc-
tions in the glycan content on hGGT1 immuno-captured
from three distinct sources. Despite significant differences
in the complexity of the hGGT1 samples, the immobilized
hGGT1 antibody reproducibly captured the target glyco-
protein with equivalent efficiency, demonstrating that
there was no inherent technical bias in this phase of the
analysis (Figures 6C and 7). Moreover, this observation
underscores the capacity of this platform to accommodate
sample preparations with variable enrichment of the ana-
lytical target. In general, the lectin binding patterns illumi-
nated by the ALSA analysis were consistent with known,
quantifiable differences in the glycan content on hGGT1
that we had previously identified by mass spectrometry
(Figure 4 and [17]). However, unlike other complementary
approaches, discriminatory distinctions in glycan content
could be detected on hGGT1 using sub-microgram quan-
tities of total protein within the complex tissue sample
pools, and in the case of the Pp-hGGT1, sub-nanogram
amounts of total protein were successfully analyzed. As
expected, lectins (MVN, GNL, and ConA) with high affin-
ity for high-mannose structures exhibited strong, prefer-
ential binding for immuno-captured Pp-hGGT1, which
is exclusively modified with high-mannose structures
(Figures 4 and 7 and Table 3). In contrast, Pha-E exhib-
ited unique affinity for kidney-expressed hGGT1 (Figure 7
and Table 3). Pha-E is selective for complex type N-glycans
containing bisecting GlcNAc motifs [54]. This structural
feature was predicted by previous mass spectrometric and
enzymatic analyses to be unique to the kidney hGGT1
pool examined in this study (Figure 3 and [17,19]), provid-
ing validity to the differential ALSA binding pattern. DSL,
on the other hand, exhibited high affinity for kidney
hGGT1, moderate affinity for liver hGGT1, and no detect-
able affinity for Pichia pastoris-expressed hGGT1 by
ALSA (Figure 7 and Table 3). In light of the fact that DSL
is known to bind N-acetyl-lactosamine motifs (Galβ1-
4GlcNAc) [56,57], a feature unique to hybrid or complex
type N-glycans, the ALSA binding pattern exhibited by
this lectin is consistent with the greater size and complex-
ity of N-glycans on kidney hGGT1 relative to those identi-
fied on the liver enzyme and with the absence of these
structural motifs on the Pichia pastoris-expressed enzyme
(Figure 4 and [17]). These patterns were faithfully repli-
cated in standard Western blots of immunoprecipi-
tated hGGT1 samples, albeit consuming approximately 60
times more primary sample. Therefore, these results not
only provide proof of concept support for the validity ofthe ALSA platform in detecting differences in glycosyla-
tion patterns on hGGT1 but also demonstrate that pri-
mary screening with ALSA using limited amounts of
biological material can lead to responsible conservation of
primary samples that can subsequently be used for other
complementary targeted profiling techniques. A broader
search of lectins, or application of lectin arrays [58], is
needed to identify ALSA-exploitable lectins that detect
features specific to liver-derived hGGT1. However, liver
glycosylation frequently includes sialic acid [17,59], whose
negative charges can inhibit the binding of certain lectins.
The lectins in this study do not bind sialylated motifs. We
probed for sialic acid modifications on the immunocap-
tured hGGT1, but we had only low binding with lectins
that detect sialylation. We are working to improve the
binding of these lectins in the ALSA. Quantitative binding
data from an expanded lectin pool may predict glycan mo-
tifs that are unique to hGGT1 from each of these sources
[60]. Interestingly, GSL-1 and ECL, which are known for
Gal-associated motifs not expected on Pichia pastoris-
expressed glycoproteins, exhibited substantial binding
to Pp-hGGT1 (Figures 6C and 7). However, even these
lectins show weak cross-reactivity with certain high man-
nose N-glycans in publically available databases (www.
functionalglycomics.org). This suggests that certain N-
glycans formed by the Pichia pastoris strain employed
here are able to adopt a conformation that can be recog-
nized by GSL-1 and ECL.
Conclusion
Based on the promising attributes of this analytical ap-
proach, we anticipate that this adapted version of the
ALSA platform can be applied to directly survey the
manner and extent in which altered glycosylation pat-
terns on hGGT1 positively correlate with various pri-
mary malignancies and other relevant pathologies in
order to evaluate their potential for providing diagnostic




The nucleotide sequence for the open-reading frame
(ORF) of MVN (EMBL accession AM041066) was syn-
thesized with flanking NdeI and BamHI restriction sites
in the pUC57 shuttle vector GenScript (Piscataway, NJ).
The MVN ORF was transferred into the E. coli expres-
sion construct pET-15b (Invitrogen, Grand Island, NY),
using NdeI and BamHI, where it was expected to encode
the full-length protein with an N-terminal hexahistadine
tag. The resultant construct was transformed into E. coli
BL21 (DE3) and transformants were isolated at 37°C on
Luria-Bertani (LB) agarose media containing 100 μg/mL
ampicillin. A clonal transformant was propagated at 37°C
West et al. BMC Biotechnology    Page 13 of 16to an OD600 of ~0.6. The culture was then cooled to room
temperature in a water bath, supplemented with isopropyl
β-D-1-thiogalactopyranoside (IPTG) to 0.5 mM, and
shaken for another 3 h at 25°C. Cells were harvested at
4,000 × g for 15 min at room temperature, resuspended in
Binding Buffer (50 mM sodium phosphate, pH 8.0,
300 mM NaCl, 1 μM leupeptin, 1 μg/mL aprotinin) con-
taining 10 mM imidazole, and lysed in an ice-cold French
Press. The lysate was centrifuged at 10,000 × g for 20 min
at 4°C, and the clarified supernatant loaded onto Perfect-
Pro Ni-NTA (5Prime, Gaithersburg, MA) column. The
column was washed with 20 bed volumes of Binding Buf-
fer containing 20 mM imidazole, and the affinity-bound
protein was eluted with Binding Buffer containing 250 mM
imidazole. Fractions containing affinity-purified MVN [as
monitored by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE)] were pooled and dialyzed
against phosphate-buffered saline (PBS: 10 mM Na2HPO4,
1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4).
MVN was biotinylated using the EZ-Link NHS-SS- Bio-
tinylation kit (Pierce, Rockland, IL), according to the man-
ufacturer’s protocol, and then fractionated away from
unconjugated biotin on a Sephadex G-25 (Sigma-Aldrich,
St. Louis, MO) column equilibrated in PBS. The resulting
biotinylated MVN stock (1.0 mg/mL) was supplemented
with 0.05% sodium azide and stored at 4°C.Glycan array analysis
The glycan array data were collected by Core H of the
Consortium for Functional Glycomics (CFG), using bio-
tinylated MVN and Alexa Fluor 488-conjugated avidin
(Invitrogen) on Version 5.0 of the printed glycan array,
according to protocols that were published previously
[61]. Version 5.0 of the glycan array consists of 611 unique
glycans in replicates of six.Purification of human GGT1 from Pichia pastoris
Recombinant glycosylated human GGT1 was affinity-
purified from Pichia pastoris X-33 strain [16,44], and ali-
quots (0.25 mg/mL) were stored at −80°C in 25 mM
Tris–HCl, 1 mM dithiothreitol, 0.5 mM EDTA, pH 8.0.Mass spectrometric analyses
Release of N-Glycans
N-glycans were released from 5 μg of recombinant
hGGT1 using peptide:N-glycosidase F (PNGase F, New
England Biolabs, Ipswich, MA) and then purified, using
Sep-Pak C18 columns (Waters Corp., Milford, MA)
and activated charcoal Carbograph cartridges (Harvard
Apparatus, Holliston, MA). The N-glycan pool was then
dried and resuspended in 20 μL of 50% methanol/50%
H2O, as described previously [62].Glycomic analysis
N-glycans (0.5 μL) were analyzed by MALDI-TOF-MS
in positive ion mode on an Ultraflex II mass spectrometer
(Bruker Daltonics, Billerica, MA) with a SMARTbeam
laser, using 2,5-dihydroxybenzoic acid, as described [62].
A dextrin ladder (Mr 500–3000, V-laboratories, Covington,
LA) was spotted and analyzed in parallel as an external
mass calibrant. Mass accuracy was typically <50 ppm for
glycans.Glycopeptide analysis
Tryptic digests were prepared and analyzed on a QSTAR
Elite hybrid quadrupole-TOF mass spectrometer (Applied
Biosystems, Grand Island, NY) equipped with a nanospray
ionization source (Ultimate 3000, Dionex, Sunnyvale, CA),
as described previously [62]. Briefly, 1.2 μg of trypsinized
protein was eluted from a C18 column using acetonitrile/
TFA directly into the mass spectrometer programmed to
perform MS/MS fragmentation on the three most abun-
dant ions under data-dependent conditions. Candidate
glycopeptides were manually identified within the data set
by probing the entire LC/MS-MS run for mass matches
against predicted glycopeptides and expanded by the in-
clusion of glycans of related compositions, as informed by
the glycans identified in the glycomics data. Assuming
equal ionization efficiency of each glycoform at a particu-
lar N-glycosylation site, the relative abundance of each
glycoform on a single glycosylation site was determined
by summing the total ion intensities for all of the glyco-
forms within a glycopeptide family over the entire elution
window. Each total ion intensity was then calculated as a
percentage relative to the other family members. The re-
ported percentages represent the average of at least three
separate LC/MS-MS experiments.Tissue extracts and sample preparations
Normal human kidney and liver tissues were obtained
from the National Disease Research Interchange (Phila-
delphia, PA) and stored at −80°C. CHAPS-solubilized
membrane fractions containing hGGT1 were prepared
as described previously [17]. Using a standardized quan-
titative biochemical assay for GGT1 transpeptidation ac-
tivity [44], tissue extracts and aliquots of Pichia pastoris-
expressed hGGT1 were volume-normalized, such that
equivalent total units of hGGT1 activity from each sam-
ple pool were diluted into 25 mM Tris–HCl buffer
(pH 7.4) containing 0.5% CHAPS. The total protein con-
centrations of the activity-normalized samples used for
ALSA analyses were 4.8, 25.5, and 0.007 mg/mL for kid-
ney, liver, and Pichia pastoris-expressed hGGT1 prepara-
tions, respectively. These studies were approved by the
Institutional Review Board at the University of Oklahoma
Health Sciences Center under IRB Protocol #11000.
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Antibody microarrays were prepared as previously de-
scribed [55]. A microarrayer (2470 Arrayer, Aushon
Biosystems, Billerica, MA) was used to spot subnanoliter
droplets of each antibody solution, prepared at 250 μg/mL
in 1X PBS, on the surfaces of ultrathin nitrocellulose-
coated glass microscope slides (PATH slides, Grace
Bio-Labs, Bend, OR). Forty-eight identical arrays were
printed on each slide, with each array consisting of the
antibody targeting hGGT1, as well as negative and positive
control antibodies, printed in six replicates. A wax border
was imprinted around each of the arrays to define hydro-
phobic boundaries (SlideImprinter, The Gel Company,
San Francisco, CA). For chemical derivatization of the
printed antibodies, each slide was incubated in 150 mM
sodium metaperiodate diluted in 0.02 M sodium acetate
(pH 5.5) for two hours at 4°C, washed in 0.02 M sodium
acetate (pH 5.5) for three minutes at room temperature,
and then incubated in 0.02 M sodium acetate contain-
ing 10 mM L-glutamic acid for two hours at room
temperature. Slides were then washed three times in
PBS containing 0.5% Tween-20, centrifuged briefly, and
then were stored at 4°C in a desiccated, vacuum-sealed
slide box until use.
Sandwich assays
Assays were performed similar to previously described
methods [26,55]. Aliquots of volume-and activity-normalized
stocks of kidney and liver tissue extracts or Pichia pas-
toris-expressed hGGT1 were supplemented with SDS to
a final concentration 0.5% and denatured at 100°C for
10 minutes in order to dissociate hGGT1 from co-purifying
membrane-bound glycoproteins. Samples were then
cooled to room temperature and then diluted two-fold
into a PBS buffer containing 0.1% Brij, 0.1% Tween-20
and 50 μg/mL of protease inhibitor. An IgG/IgY cocktail
consisting of a final concentration of 400 μg/mL goat and
sheep IgG and 800 μg/mL rabbit and mouse IgG (Jackson
Immunoresearch, West Grove, PA) was added to each
sample to eliminate non-specific binding to the printed
antibodies. Slides were blocked in a solution containing
PBS-0.5% Tween-20 buffer with the addition of 1% BSA.
Six microliters of sample were then applied to each array
overnight at 4°C. The arrays were washed in three changes
of PBS/0.1% Tween-20 for three minutes each and dried by
centrifugation (Eppendorf 5810R, rotor A-4-62, 1500 × g
for three minutes). Captured antigens were detected
with biotinylated detection reagents at a concentra-
tion of 1–10 μg/mL for one hour at room temperature
followed by incubation with 1 μg/mL streptavidin-
phycoerythrin (Roche Applied Science, Indianapolis, IN).
The slides were washed and dried as above and scanned
for fluorescence emission at 575 nm using a microarray
scanner (LS Reloaded, TECAN, Durham, NC). At leastthree independent sample array analyses were conducted
for each ALSA experiment. The data analysis and prepar-
ation was performed using Microsoft Excel and Canvas X.
Lectin blots
Equivalent units of hGGT1 activity from Pichia pastoris-
expressed hGGT1 stocks and from normal human
kidney and liver tissue extracts were subjected to im-
munoprecipitation with GGT129 antibody and bovine
serum albumin-blocked protein G-Sepharose beads (GE
Healthcare, Piscataway, NJ), as described [15]. Bound
proteins were eluted in 50 μL of Laemmli sample buffer
(2% SDS, 5% glycerol, 5% 2-mercaptoethanol, 0.002%
bromphenol blue, 62.5 mM Tris–HCl, pH 6.8) for 10 min
at 100°C, and five microliter aliquots of each eluate were
resolved on 8% SDS-PAGE gels. The resolved proteins
were electroblotted onto nitrocellulose membranes and
blocked overnight at 4°C in Carbo-Free blocking agent
(Vector Labs, Burlingame, CA). Lectin blotting was con-
ducted using the appropriate biotinylated lectins diluted
in PBS containing 1 mM calcium chloride and 0.05%
Tween-20 (PBST). Each membrane was incubated in
PBST with either 1.0 μg/mL biotinylated MVN (described
herein), 1.0 μg/mL biotinylated Datura stramonium lectin
(DSL, Vector Labs), or 0.2 μg/mL biotinylated Phaseolus
vulgaris-Erythroagglutinin (Pha-E, Vector Labs) for 1 h
at room temperature. Membranes were then washed
six times for five minutes with PBST and incubated with
0.5 μg/mL horseradish peroxidase-conjugated avidin
(avidin-HRP, Vector Labs) for 1 h at room temperature in
PBST. The membranes were subjected to an additional
round of washing with PBST, and the blots were visualized
by chemiluminescence, according to the manufacturer's
protocol (ECL Plus, GE Healthcare). Western blotting
against the large subunit of GGT1 was carried out as de-
scribed previously [15].
Additional file
Additional file 1: Figure S1. Expanded view of Figure 8, hGGT1 lectin
blotting confirms differential ALSA binding affinities. Membrane extracts
from normal human kidney and liver tissue or Pichia pastoris-expressed
hGGT1 were activity-normalized and subjected to immunoprecipitation
with a polyclonal anti-hGGT1 large subunit antibody. Equal volumes from
each immunoprecipitation eluate were resolved by SDS-PAGE and affinity
blotted with anti-hGGT1 (hGGT1 blot) or the biotinylated lectins, microvirin
(MVN blot), Phaseolus vulgaris Erythroagglutinin (Pha-E blot), and Datura
stramonium lectin (DSL blot). Position of molecular weight markers are
shown on right.
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